Syndax Pharmaceuticals (SNDX) Cash from Investing Activities (2015 - 2026)

Syndax Pharmaceuticals' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 59.22% year-over-year to $38.4 million in Q1 2026; TTM through Mar 2026 was $234.3 million, a 993.05% increase from a year earlier, with the FY2025 full-year figure at $290.0 million, up 231.97% from the prior year.
• Cash from Investing Activities fell to $38.4 million in Q1 2026 per SNDX's latest filing, from $81.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $94.1 million in Q1 2025 and bottomed at -$269.0 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $38.4 million (2026), against an average of $2.4 million.
• Across the five-year window, Cash from Investing Activities surged 689.97% in 2023 and sank 1551.15% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$137.6 million in 2022, then soared by 88.16% to -$16.3 million in 2023, then sank by 1551.15% to -$269.0 million in 2024, then jumped by 130.33% to $81.6 million in 2025, then slumped by 52.94% to $38.4 million in 2026.
• Per Business Quant, the three latest SNDX Cash from Investing Activities figures stand at $38.4 million (Q1 2026), $81.6 million (Q4 2025), and $72.4 million (Q3 2025).